RESEARCH TRIANGLE PARK, N.C., May 3, 2011 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that it will host a conference call on Friday, May 13, 2011 at 8:30 A.M. ET to discuss first quarter 2011 financial results. The Company will report first quarter 2011 financial results after the close of the market on Thursday, May 12, 2011.
To participate in the live call, please dial (877) 670 - 9784 (U.S. and Canada) or (970) 315 - 0430 (international), five to ten minutes prior to the start of the call. A live audio webcast will also be available in the "Investors" section of the Tranzyme Pharma website, http://www.tranzyme.com.
A replay of the conference call will be available beginning May 13, 2011 at 11:30 A.M. ET and ending on May 20, 2011. Investors may listen to the replay by dialing (800) 642-1687 (U.S. and Canada) or (706) 645-9291 (international), with the passcode 63772004. The webcast will also be archived for on-demand listening for 30 days at www.tranzyme.com.
The company also announced that Phase 2 data of TZP-102, an orally‑administered ghrelin agonist in development for diabetic gastroparesis, an upper gastrointestinal (GI) motility disorder, will be presented during a poster session at Digestive Disease Week (DDW) taking place at McCormick Place in Chicago, IL from May 7 – 10, 2011.
Richard W. McCallum, M.D., Professor and Founding Chairman of the Department of Internal Medicine, Texas Tech University Health Sciences Center at El Paso, TX will present poster Tu1365 entitled "TZP-102, Ghrelin Agonist Phase 2 Data: The Improvement in Symptoms of Gastroparesis (Nausea, Early Satiety, Bloating and Abdominal Pain) Significantly Correlated With Patient Rating of Overall Treatment Effect." The poster will be on display Tuesday, May 10, 2011 from 12:00 P.M. to 2:00 P.M. CT in Hall A at McCormick Place. Data are embargoed until 8:00 A.M. CT on May 10.
About Digestive Disease Week
Digestive Disease Week (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. DDW is jointly sponsored by the American Association for the Study of Liver Diseases, the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy and the Society for Surgery of the Alimentary Tract. The meeting showcases approximately 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. For more information, visit http://www.ddw.org/">www.ddw.org.
About Tranzyme Pharma
Tranzyme Pharma is a clinical‑stage biopharmaceutical company focused on discovering, developing and commercializing novel, first-in-class small molecule therapeutics for the treatment of acute (hospital‑based) and chronic gastrointestinal (GI) motility disorders. All of Tranzyme's product candidates have been discovered using its proprietary drug discovery (chemistry) technology, MATCH™, which enables the construction of synthetic libraries of drug-like, macrocyclic compounds in a predictable and efficient manner.
The Tranzyme, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=9438